Name: 글로벌 시장 동향
SKU: PH945
Availability: InStock

보고서 요약(국문)

개요
전 세계 비소세포폐암 시장은 2022년 254억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 8.4%의 성장률을 보이며 2030년에는 474억 달러에 이를 것으로 예상됩니다. 비소세포폐암 시장의 성장은 발병률 증가, 연구 개발 발전, 맞춤형 치료, 신약 파이프라인 개발, 정부 정책 등의 요인에 의해 주도되고 있습니다.
비소세포폐암 치료 전략은 암의 진행 정도를 나타내는 병기에 따라 결정됩니다. 수술, 방사선 치료, 화학 요법, 표적 치료, 면역 요법 등이 가능한 치료법입니다. 치료 방법 선택은 종양의 크기와 위치, 주변 림프절이나 다른 신체 부위로의 전이 여부, 환자의 전반적인 건강 상태 등 여러 변수에 의해 영향을 받습니다.

시장 동향
비소세포폐암 치료제에 대한 FDA 승인 증가가 전 세계 비소세포폐암 시장 성장을 견인하고 있습니다.
2022년 8월, FDA 승인 검사를 통해 MET(중배엽-상피 전환) 엑손 14 스키핑 변이가 확인된 전이성 비소세포폐암(NSCLC) 성인 환자를 대상으로, FDA는 캡마티닙(타브렉타, 노바티스 제약)을 해당 질환 치료제로 정식 승인했습니다.
또한, 2022년 11월에는 리제네론 제약이 EGFR, ALK 또는 ROS1 변이가 없는 진행성 비소세포폐암(NSCLC) 성인 환자의 1차 치료제로 백금 기반 항암화학요법과 병용하는 PD-1 억제제 리브타요(세미플리맙-rwlc)를 FDA 승인했다고 발표했습니다.

환자는 확정적인 화학방사선 요법이나 외과적 절제가 불가능한 국소 또는 전이성 진행성 종양을 가지고 있어야 합니다. 이 병용 요법은 조직학적 유형이나 PD-L1 발현 여부와 관계없이 환자 치료에 사용될 수 있습니다.
연구 활동의 증가가 전 세계 비소세포폐암 시장 성장을 견인하고 있습니다.
2023년 7월, 아스트라제네카와 다이이치산쿄가 개발한 TROP2 표적 항체 약물 병용 요법은 기존에 치료받은 적이 있는 국소 진행성 또는 전이성 질환 환자를 대상으로 한 첫 번째 3상 임상 데이터에서 기존 화학 요법 대비 무진행 생존 기간이 통계적으로 유의미하게 증가한 것으로 나타났습니다.

TROPION-Lung01 3상 임상시험의 고무적인 고위급 결과에 따르면, 국소 진행성 또는 전이성 비소세포폐암(NSCLC) 환자 중 최소 한 가지 이상의 이전 치료를 받은 환자에서 다토포타맙 데룩스테칸(Dato-DXd)은 현재 표준 항암화학요법인 도세탁셀 대비 무진행 생존(PFS)이라는 두 가지 주요 평가변수에서 통계적으로 유의미한 개선을 보였습니다.
전체 생존(OS)이라는 두 가지 주요 평가변수에서 다토포타맙 데룩스테칸이 도세탁셀보다 초기에는 우세한 경향을 보였지만, 데이터가 충분히 성숙되지 않아 이번 중간 분석에서는 사전에 정해진 통계적 유의성 수준에 도달하지 못했습니다. OS에 대한 평가는 예정대로 진행될 것입니다.
비소세포폐암 치료와 관련된 부작용이 전 세계 비소세포폐암 시장 성장을 저해하고 있습니다.
비소세포폐암 치료와 관련된 부작용이 시장 성장을 저해하고 있습니다. 심각하거나 치명적일 수 있는 면역 매개 이상 반응은 모든 장기 계통이나 조직에서 발생할 수 있으며, 여러 신체 계통에 동시에 영향을 미칠 수 있습니다. 폐렴, 대장염, 간염, 내분비 질환, 신염, 피부 반응, 고형 장기 이식 거부 반응, 동종 조혈 줄기세포 이식 합병증 등은 키트루다(KEYTRUDA) 치료 중 또는 치료 후 언제든지 발생할 수 있는 면역 매개 이상 반응의 몇 가지 예입니다.
또한, 키트루다 투여와 관련된 심각하거나 치명적인 반응이 발생할 수 있습니다. 임산부에게 투여할 경우, 키트루다는 작용 기전으로 인해 태아에게 해를 끼칠 가능성이 있습니다.
세분화 분석
전 세계 비소세포폐암 시장은 유형, 치료법, 최종 사용자 및 지역별로 세분화됩니다.

화학요법 부문은 예측 기간 동안 시장에서 지배적인 위치를 유지할 것으로 예상됩니다.
화학요법 부문은 2022년 비소세포폐암 시장에서 약 45.1%의 점유율을 차지하며 가장 높은 시장 점유율을 기록했습니다. 전이성 질환 환자를 위한 많은 발전이 있었음에도 불구하고, 수술은 여전히 1B기, 2기, 3A기 비소세포폐암 환자에게 가장 일반적인 치료법입니다.
미국 식품의약국(FDA)은 2023년 1월, 머크의 항PD-1 치료제인 키트루다(KEYTRUDA)를 1B기(T2a 4cm), 2기 또는 3A기 비소세포폐암(NSCLC) 성인 환자의 수술적 절제 및 백금 기반 화학요법 후 보조 요법으로 단독 투여하는 것을 승인했습니다.

지리적 시장 침투
북미, 전 세계 비소세포폐암 시장에서 지배적인 위치 차지
북미는 예측 기간 동안 전체 시장 점유율의 약 38.3%를 차지할 것으로 예상됩니다. 폐암은 전 세계적으로 두 번째로 흔한 암입니다. 미국에서 진단되는 모든 폐암의 81%가 비소세포폐암(NSCLC)으로, 가장 흔한 유형의 질병입니다. 2023년 미국에서는 238,340명의 성인(남성 117,550명, 여성 120,790명)이 폐암 진단을 받을 것으로 예상됩니다. 2020년에는 전 세계적으로 2,206,771건의 폐암 진단이 있을 것으로 추정됩니다. 이 통계에는 비소세포폐암과 소세포폐암이 모두 포함됩니다.
현재 흑인 여성과 백인 여성의 폐암 발병률은 남성보다 낮습니다. 흑인 남성은 백인 남성보다 폐암 발병률이 12% 더 높으며, 흑인 남성은 폐암 발병률이 가장 높은 집단입니다. 흑인 여성은 백인 여성보다 폐암 발병률이 16% 낮습니다. 폐암 위험은 나이가 들수록 증가합니다. 추정에 따르면 폐암 환자의 약 53%가 70세 이상입니다. 65세 이상은 진단 건수의 83%를 차지하는 주요 연령층으로 여겨집니다. 여성의 경우 대부분 75세에서 79세 사이에 발견되는 반면, 남성은 80세에서 84세 사이에 비소세포폐암(NSCLC) 진단을 받을 가능성이 가장 높습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Eli Lilly and Company, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Astellas 등이 있습니다.

코로나19 영향 분석
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁은 지정학적 불안정과 경제적 불확실성으로 인해 의료 시설 부족을 초래하여 비소세포폐암 시장에 영향을 미칠 수 있습니다. 분쟁으로 인해 의료 기관 및 서비스가 영향을 받을 경우, 비소세포폐암 치료와 관련된 임상 시험 및 연구 프로젝트가 차질을 빚을 수 있습니다. 연구가 중단되거나 차질을 빚으면 새로운 치료법 개발이 지연될 수 있습니다.
지정학적 불확실성은 특히 의료 부문에 대한 국제 투자 감소를 초래할 수 있습니다. 이는 비소세포폐암 연구, 개발 및 인프라에 할당되는 자금 규모에 영향을 미칠 수 있습니다.
인공지능 분석:
인공지능(AI)은 데이터 분석의 다양한 측면을 개선하기 위해 비소세포폐암 시장에서 점점 더 많이 활용되고 있습니다. 영상의학과 의사는 AI 알고리즘을 사용하여 CT 및 X선 스캔 데이터를 분석하고 비소세포폐암을 나타낼 수 있는 패턴과 이상 징후를 찾을 수 있습니다. 이러한 알고리즘은 진단 속도와 정확도를 향상시키는 데 도움이 될 수 있습니다. 또한, 폐 종양 및 병변의 의료 영상은 AI를 사용하여 분할할 수 있으며, 이를 통해 종양의 크기, 모양 및 위치를 더욱 자세히 파악할 수 있습니다. 치료 계획 및 모니터링에는 이러한 정보가 필요합니다.
약물 계열별
• 상피세포 성장인자 수용체(EGFR) 억제제
• 역형성 림프종 키나제(ALK) 억제제
• ROS1 억제제
• BRAF 억제제
• 기타
유형별
• 편평세포암
• 대세포암
• 선암
• 기타
치료법별
• 화학요법
• 표적 치료
• 면역요법
최종 사용자별
• 병원
• 가정 간호
• 전문 클리닉
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2022년 12월, 싱가포르 과학기술연구청(A*STAR) 산하 국가 신약 개발 플랫폼인 실험 신약 개발 센터(EDDC)와 선도적인 제약 기술 기업 XtalPi는 비소세포폐암(NSCLC)의 새로운 치료법 개발을 위한 전략적 파트너십을 발표했습니다.
본 보고서를 구매해야 하는 이유:

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 비소세포폐암 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악할 수 있습니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 비소세포폐암 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

본 글로벌 비소세포폐암 시장 보고서는 약 61개의 표, 69개의 그림, 그리고 195페이지 분량으로 구성되어 있습니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Non Small-Cell Lung Cancer Market reached US$ 25.4 billion in 2022 and is expected to reach US$ 47.4 billion by 2030 growing with a CAGR of 8.4% during the forecast period 2023-2030. The non-small-cell lung cancer market is driven by factors such as increasing incidence, advancements in research and development, personalized medicine, pipeline developments, and government initiatives.
The non-small-cell lung cancer treatment strategy is determined by the cancer's stage, which reflects how far along it has progressed. Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy are all possible forms of treatment. The selection of a course of treatment is impacted by a number of variables, including the size and location of the tumor, whether it has progressed to surrounding lymph nodes or distant regions of the body, and the patient's general condition.
Market Dynamics
The Increasing FDA Approval for Non-Small-Cell Lung Cancer Treatment is Driving the Global Non-Small-Cell Lung Cancer Market Growth
In August 2022, for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food and Drug Administration has given capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) regular approval for this diseases.
In addition, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line Treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who do not have EGFR, ALK, or ROS1 aberrations.
Patients must either have locally or metastatically advanced tumors that are not amenable to definitive chemoradiation or surgical excision. This combination may be used to treat patients regardless of histology or PD-L1 expression.
The Increasing Research Activities are Driving The Global Non-Small-Cell Lung Cancer Market Growth
In July 2023, the TROP2-directed antibody drug combination developed by AstraZeneca and Daiichi Sankyo showed a statistically significant increase in progression-free survival compared to conventional chemotherapy in previously treated locally progressed or metastatic illness in the first Phase III data.
Datopotamab deruxtecan (Dato-DXd) showed a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy, according to encouraging high-level findings from the TROPION-Lung01 Phase III trial.
There was an early tendency in favor of datopotamab deruxtecan versus docetaxel for the dual primary endpoint of overall survival (OS), but it did not reach the predetermined level of statistical significance at this interim analysis because the data were not mature. The experiment will proceed as scheduled to evaluate OS at a more mature stage.
Side Effects Associated with Non-Small-Cell Lung Cancer Therapy are Hampering the Global Non-Small-Cell Lung Cancer Market Growth
Side effects associated with non-small-cell lung cancer therapy restraining the market growth. Adverse immune-mediated reactions, which can be serious or lethal, can happen in any organ system or tissue and can influence many bodily systems at once. Pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic responses, solid organ transplant rejection, and difficulties from allogeneic hematopoietic stem cell transplantation are a few examples of immune-mediated adverse reactions that can happen at any moment during or after therapy with KEYTRUDA.
Additionally, serious or fatal infusion-related responses to KEYTRUDA are possible. When given to a pregnant woman, KEYTRUDA has the potential to harm the fetus due to its mode of action.
Segment Analysis
The global non-small-cell lung cancer market is segmented based on type, treatment, end-user and region.
The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period
The chemotherapy segment accounted for the highest market stake accounting for approximately 45.1% of the non-small-cell lung cancer market in 2022. Surgery is still the most common form of treatment for people with stage IB, stage II, and stage IIIA non-small cell lung cancer, despite the fact that there have been numerous advancements for patients with metastatic disease.
The U.S. Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent in January 2023 for adjuvant Treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimeters [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
Geographical Penetration
North America Holds a Dominant Position in the Global Non-Small-Cell Lung Cancer Market
North America is estimated to hold around 38.3% of the total market share throughout the forecast period. Lung cancer is the second most prevalent cancer to be diagnosed globally. With 81% of all lung cancer diagnoses in the US being NSCLC, it is the most prevalent kind of disease. Lung cancer will be discovered in 238,340 adults in the United States in 2023 (117,550 men and 120,790 women). In 2020, there will likely be 2,206,771 lung cancer diagnoses worldwide. Both NSCLC and small cell lung cancer are included in these statistics.
Black and White women currently experience lower incidence rates than men. Black males are 12% more likely than White men to have lung cancer, which is the group with the highest lung cancer rates. Lung cancer is 16% less likely to affect Black women than White women. Lung cancer risk rises with advancing age. Approximately 53% of those with the condition are 70 years of age or older, according to estimates. People 65 and older are thought to be the target audience for 83% of diagnoses. While the majority of cases in women are discovered between the ages of 75 and 79, men are most likely to be diagnosed with NSCLC between the ages of 80 and 84.
Competitive Landscape
The major global players in the market include Eli Lilly and Company, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Astellas among others.
COVID-19 Impact Analysis
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war may affect the non-small-cell lung cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Clinical trials and research projects linked to NSCLC treatments could be affected if the conflict affects healthcare institutions and services. The creation of novel treatments could be slowed down by research pauses or interruptions.
Geopolitical unpredictability may cause a decline in international investments, especially those in the healthcare sector. This might have an effect on the amount of money allocated to NSCLC research, development, and infrastructure.
Artificial Intelligence Analysis:
Artificial intelligence (AI) is increasingly being used in the non-small-cell lung cancer market to improve various aspects of data analysis. Radiologists can use AI algorithms to help them analyze CT and X-ray scan data to look for patterns and abnormalities that can indicate NSCLC. These algorithms can aid in enhancing the speed and accuracy of diagnosis. In addition, medical images of lung tumors and lesions can be segmented using AI to provide a more thorough understanding of their size, shape, and location. Planning and monitoring treatments need the use of this information.
By Drug Class
• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• Anaplastic Lymphoma Kinase (ALK) Inhibitors
• ROS1 Inhibitors
• BRAF Inhibitors
• Others
By Type
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others
By Treatment
• Chemotherapy
• Targeted Therapy
• Immunotherapy
By End-user
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In December 2022, the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), and pioneering pharmaceutical technology company XtalPi, announced a strategic partnership to find new Treatment options for non-small cell lung cancer (NSCLC).
Why Purchase the Report?
• To visualize the global non-small-cell lung cancer market segmentation based on the type, treatment, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of non-small-cell lung cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global non-small-cell lung cancer market report would provide approximately 61 tables, 69 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Type
3.3. Snippet by Treatment
3.4. Snippet by End-user
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with non-small-cell lung cancer
4.1.3. Opportunity
4.1.3.1. Increasing research activities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Drug Class
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
9.4. ROS1 Inhibitors
9.5. BRAF Inhibitors
9.6. Others
10. By Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.1.2. Market Attractiveness Index, By Type
10.2. Squamous Cell Carcinoma*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Large Cell Carcinoma
10.4. Adenocarcinoma
10.5. Others
11. By Treatment
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.1.2. Market Attractiveness Index, By Treatment
11.2. Chemotherapy*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Targeted Therapy
11.4. Immunotherapy
12. By End-user
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.1.2. Market Attractiveness Index, By End-user
12.2. Hospitals*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Homecare
12.4. Specialty Clinics
12.5. Others
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. Company Profiles
15.1. Eli Lilly and Company*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi
15.3. Novartis AG
15.4. F. Hoffmann-La Roche Ltd
15.5. Merck & Co., Inc.
15.6. Pfizer Inc.
15.7. AstraZeneca
15.8. Boehringer Ingelheim
15.9. Bristol-Myers Squibb Company
15.10. Astellas
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Eli Lilly and Company, 4.	Key Developments, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Astellas

표 목록 (Tables)

List of Tables

Table 1 Global Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Non-Small-Cell Lung Cancer Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Non-Small-Cell Lung Cancer Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Non-Small-Cell Lung Cancer Market Value, By End-user, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Non-Small-Cell Lung Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 8 Global Non-Small-Cell Lung Cancer Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Non-Small-Cell Lung Cancer Market Value, By Type, 2021-2030 (US$ Billion)

Table 10 Global Non-Small-Cell Lung Cancer Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Non-Small-Cell Lung Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 12 Global Non-Small-Cell Lung Cancer Market Value, By End-user, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Non-Small-Cell Lung Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 14 Global Non-Small-Cell Lung Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Non-Small-Cell Lung Cancer Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 17 North America Non-Small-Cell Lung Cancer Market Value, By Type, 2021-2030 (US$ Billion)

Table 18 North America Non-Small-Cell Lung Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 19 North America Non-Small-Cell Lung Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 20 North America Non-Small-Cell Lung Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 22 South America Non-Small-Cell Lung Cancer Market Value, By Type, 2021-2030 (US$ Billion)

Table 23 South America Non-Small-Cell Lung Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 24 South America Non-Small-Cell Lung Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 25 South America Non-Small-Cell Lung Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 27 Europe Non-Small-Cell Lung Cancer Market Value, By Type, 2021-2030 (US$ Billion)

Table 28 Europe Non-Small-Cell Lung Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 29 Europe Non-Small-Cell Lung Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 30 Europe Non-Small-Cell Lung Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, By Type, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Non-Small-Cell Lung Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Non-Small-Cell Lung Cancer Market Value, By Type, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Non-Small-Cell Lung Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Non-Small-Cell Lung Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 40 Eli Lilly and Company: Overview

Table 41 Eli Lilly and Company: Product Portfolio

Table 42 Eli Lilly and Company: Key Developments

Table 43 Sanofi: Overview

Table 44 Sanofi: Product Portfolio

Table 45 Sanofi: Key Developments

Table 46 Novartis AG: Overview

Table 47 Novartis AG: Product Portfolio

Table 48 Novartis AG: Key Developments

Table 49 F. Hoffmann-La Roche Ltd: Overview

Table 50 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 51 F. Hoffmann-La Roche Ltd: Key Developments

Table 52 Merck & Co., Inc.: Overview

Table 53 Merck & Co., Inc.: Product Portfolio

Table 54 Merck & Co., Inc.: Key Developments

Table 55 Pfizer Inc.: Overview

Table 56 Pfizer Inc.: Product Portfolio

Table 57 Pfizer Inc.: Key Developments

Table 58 AstraZeneca: Overview

Table 59 AstraZeneca: Product Portfolio

Table 60 AstraZeneca: Key Developments

Table 61 Boehringer Ingelheim: Overview

Table 62 Boehringer Ingelheim: Product Portfolio

Table 63 Boehringer Ingelheim: Key Developments

Table 64 Bristol-Myers Squibb Company: Overview

Table 65 Bristol-Myers Squibb Company: Product Portfolio

Table 66 Bristol-Myers Squibb Company: Key Developments

Table 67 Astellas: Overview

Table 68 Astellas: Product Portfolio

Table 69 Astellas: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Non-Small-Cell Lung Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Non-Small-Cell Lung Cancer Market Share, By Type, 2022 & 2030 (%)

Figure 4 Global Non-Small-Cell Lung Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 5 Global Non-Small-Cell Lung Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 6 Global Non-Small-Cell Lung Cancer Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Non-Small-Cell Lung Cancer Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 8 Epidermal Growth Factor Receptor (EGFR) Inhibitors Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 9 Anaplastic Lymphoma Kinase (ALK) Inhibitors Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 10 ROS1 Inhibitors Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 11 BRAF Inhibitors Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 12 Others Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Non-Small-Cell Lung Cancer Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 14 Squamous Cell Carcinoma Type in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 15 Large Cell Carcinoma Type in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 16 Adenocarcinoma Type in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 17 Others Type in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Non-Small-Cell Lung Cancer Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 19 Chemotherapy Treatment in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 20 Targeted Therapy Treatment in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 21 Immunotherapy Treatment in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Non-Small-Cell Lung Cancer Market Y-o-Y Growth, By End-user, 2022-2030 (%)

Figure 23 Hospitals End-user in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 24 Homecare End-user in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 25 Specialty Clinics End-user in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 26 Others End-user in Global Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 27 Global Non-Small-Cell Lung Cancer Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 29 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 30 Europe Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 31 South America Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 32 Middle East and Africa Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 33 North America Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 34 North America Non-Small-Cell Lung Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 35 North America Non-Small-Cell Lung Cancer Market Share, By Type, 2022 & 2030 (%)

Figure 36 North America Non-Small-Cell Lung Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 37 North America Non-Small-Cell Lung Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 38 North America Non-Small-Cell Lung Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 39 South America Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 40 South America Non-Small-Cell Lung Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 41 South America Non-Small-Cell Lung Cancer Market Share, By Type, 2022 & 2030 (%)

Figure 42 South America Non-Small-Cell Lung Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 43 South America Non-Small-Cell Lung Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 44 South America Non-Small-Cell Lung Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 45 Europe Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 46 Europe Non-Small-Cell Lung Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 47 Europe Non-Small-Cell Lung Cancer Market Share, By Type, 2022 & 2030 (%)

Figure 48 Europe Non-Small-Cell Lung Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 49 Europe Non-Small-Cell Lung Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 50 Europe Non-Small-Cell Lung Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 51 Asia-Pacific Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 52 Asia-Pacific Non-Small-Cell Lung Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 53 Asia-Pacific Non-Small-Cell Lung Cancer Market Share, By Type, 2022 & 2030 (%)

Figure 54 Asia-Pacific Non-Small-Cell Lung Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 55 Asia-Pacific Non-Small-Cell Lung Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 56 Asia-Pacific Non-Small-Cell Lung Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 57 Middle East & Africa Non-Small-Cell Lung Cancer Market Value, 2021-2030 (US$ Billion)

Figure 58 Middle East & Africa Non-Small-Cell Lung Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 59 Middle East & Africa Non-Small-Cell Lung Cancer Market Share, By Type, 2022 & 2030 (%)

Figure 60 Middle East & Africa Non-Small-Cell Lung Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 61 Middle East & Africa Non-Small-Cell Lung Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 62 Eli Lilly and Company: Financials

Figure 63 Sanofi: Financials

Figure 64 Novartis AG: Financials

Figure 65 F. Hoffmann-La Roche Ltd: Financials

Figure 66 Merck & Co., Inc.: Financials

Figure 67 Pfizer Inc.: Financials

Figure 68 AstraZeneca: Financials

Figure 69 Boehringer Ingelheim: Financials

Figure 70 Bristol-Myers Squibb Company: Financials

Figure 71 Astellas: Financials

세계 비소세포폐암 시장 – 2023-2030

Global Non-Small-Cell Lung Cancer Market - 2023-2030